Answers are grounded in this paper and cite their sources.
Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.
No takes yet. Share an insight, caveat, or question.
Delaugerre et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: